

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 July 2011 (28.07.2011)

(10) International Publication Number
WO 2011/091417 A1

(51) International Patent Classification:
A01N 43/00 (2006.01)

(21) International Application Number:
PCT/US2011/022401

(22) International Filing Date:
25 January 2011 (25.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/297,918 25 January 2010 (25.01.2010) US
61/314,304 16 March 2010 (16.03.2010) US

(71) Applicant (for all designated States except US): **ENANTA PHARMACEUTICALS, INC.** [US/US]; 500 Arsenal Street, Watertown, MA 02457 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **QIU, Yao-Ling** [US/US]; 29 Linda Road, Andover, MA 01810 (US). **WANG, Ce** [CN/US]; 220 School Street, Apt.9, Waltham, MA 02451 (US). **PENG, Xiaowen** [CN/US]; 66 Homer Avenue, #410, Cambridge, MA 02138 (US). **YING, Lu** [CN/CN]; 4580 Duskin Road, Shanghai, 200331 (CN). **CAO, Hui** [CN/US]; 53 Hills Road, Belmont, MA 02478 (US). **OR, Yat, Sun** [US/US]; 169 Fayette Street, Watertown, MA 02472 (US).

(74) Agents: **HODA, Mahreen, Chaudhry** et al.; ELMORE PATENT LAW GROUP, 484 Groton Road, Westford, MA 01886 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HEPATITIS C VIRUS INHIBITORS

(57) Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W (I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.



WO 2011/091417 A1